{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:42:34Z","timestamp":1790026954838,"version":"4.0.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.nucmedbio.2012.05.007","type":"journal-article","created":{"date-parts":[[2012,6,26]],"date-time":"2012-06-26T01:50:24Z","timestamp":1340675424000},"page":"962-969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts"],"prefix":"10.1016","volume":"39","author":[{"given":"Morten","family":"Persson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palle","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ploug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kjaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0005","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0010","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0015","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1001\/archsurg.2010.41","article-title":"Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases","volume":"145","author":"Glazer","year":"2010","journal-title":"Arch Surg"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0020","first-page":"12","article-title":"Rational targeting of the urokinase receptor (uPAR): development of inhibitors and non-invasive imaging probes","volume":"12","author":"Kriegbaum","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0025","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00001813-200106000-00001","article-title":"The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer","volume":"12","author":"Mazar","year":"2001","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0030","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.2174\/092986708785909012","article-title":"The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition","volume":"15","author":"Jacobsen","year":"2008","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0035","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.2741\/3186","article-title":"Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer","volume":"13","author":"Rasch","year":"2008","journal-title":"Front Biosci"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0040","first-page":"4065","article-title":"Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer","volume":"54","author":"Ganesh","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0045","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0140-6736(94)91427-3","article-title":"Urokinase receptor and colorectal cancer survival","volume":"344","author":"Ganesh","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0050","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/bjc.1997.306","article-title":"Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer","volume":"75","author":"Ganesh","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0055","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jnci\/91.10.869","article-title":"Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis","volume":"91","author":"Stephens","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0060","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3109\/0284186X.2010.491086","article-title":"Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients","volume":"49","author":"Lomholt","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0065","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/ijc.24166","article-title":"Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases","volume":"124","author":"Illemann","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1178>3.0.CO;2-6","article-title":"Inhibition of colon cancer metastasis by a 3\u2032- end antisense urokinase receptor mRNA in a nude mouse model","volume":"92","author":"Wang","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0075","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/sj.bjc.6601098","article-title":"Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells","volume":"89","author":"Ahmed","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0080","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1002\/cncr.24371","article-title":"Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver","volume":"115","author":"Van Buren","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0085","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2214\/AJR.11.6797","article-title":"Molecular theranostics: a primer for the imaging professional","volume":"197","author":"Lee","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0090","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0095","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00259-010-1684-x","article-title":"Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy","volume":"38","author":"Jiang","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0100","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/0008-5472.CAN-06-2363","article-title":"[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts","volume":"67","author":"Persson","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0105","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1158\/0008-5472.CAN-06-1630","article-title":"Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule","volume":"67","author":"Tolmachev","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0110","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/0008-5472.CAN-10-1186","article-title":"Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN)","volume":"71","author":"Wild","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0115","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.2967\/jnumed.111.091629","article-title":"Targeted systemic radiotherapy with scVEGF\/177Lu leads to sustained disruption of the tumor vasculature and intratumoral apoptosis","volume":"52","author":"Blankenberg","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0120","first-page":"325","article-title":"Antiproliferative effects of 111In- or 177Lu-DOTATOC on cells exposed to low multiplicity-of-infection double-deleted vaccinia virus encoding somatostatin subtype-2 receptor","volume":"25","author":"Akinlolu","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0125","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2967\/jnumed.110.083386","article-title":"Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion","volume":"53","author":"Persson","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0130","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1158\/1078-0432.CCR-07-4434","article-title":"Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET","volume":"14","author":"Li","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0135","doi-asserted-by":"crossref","first-page":"12157","DOI":"10.1021\/bi010662g","article-title":"Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation","volume":"40","author":"Ploug","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2011.10.011","article-title":"(68)Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers","author":"Persson","year":"2012","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0145","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.pep.2006.08.011","article-title":"One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry","volume":"52","author":"Jacobsen","year":"2007","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0150","doi-asserted-by":"crossref","first-page":"10982","DOI":"10.1074\/jbc.M109.093492","article-title":"Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy","volume":"285","author":"Lin","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0155","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00665944","article-title":"Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies","volume":"33","author":"Ronne","year":"1995","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0160","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10585-005-5788-9","article-title":"Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer","volume":"22","author":"Qu","year":"2005","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0165","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2967\/jnumed.106.036020","article-title":"Indication for different mechanisms of kidney uptake of radiolabeled peptides","volume":"48","author":"Gotthardt","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0170","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s00259-009-1282-y","article-title":"Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues","volume":"37","author":"Rolleman","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0175","doi-asserted-by":"crossref","first-page":"e12965","DOI":"10.1371\/journal.pone.0012965","article-title":"Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice","volume":"5","author":"Jensen","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0180","doi-asserted-by":"crossref","first-page":"690","DOI":"10.2967\/jnumed.110.084566","article-title":"Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment","volume":"52","author":"Herrmann","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2012.05.007_bb0185","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1200\/JCO.2010.32.4939","article-title":"Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography","volume":"29","author":"Zander","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980511200128X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096980511200128X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:27:55Z","timestamp":1760848075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096980511200128X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S096980511200128X"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2012.05.007","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2012.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}